

## Product Information

KBML-149554-01/10

### FSL-AcqB(tri)

FSL-ACB(GALN(Ac-) $\alpha$ 3[Fa2]GALb)-SA1-L1

Catalogue Numbers **149554-1-R&D**

Unit size **1 mg**

Storage temperature below minus 10 °C

### Product Description

FSL-AcqB(tri) is a KODE™ technology construct designed to label hydrophobic surfaces including living cells with deacetylated blood group A trisaccharide (also known as acquired-B antigen)<sup>1</sup>. All KODE™ FSL constructs consist of three essential designable features; a functional component (F), a spacer (S), and a diacyl lipid (L).

FSL-ACB(GALN(Ac-) $\alpha$ 3[Fa2]GALb)-SA1-L1 is comprised of deacetylated blood group A trisaccharide GalN $\alpha$ 3(Fuc $\alpha$ 2)Gal $\beta$  representing F, conjugated via an O(CH<sub>2</sub>)<sub>3</sub>NH spacer (SA1) to an activated adipate derivative of dioleoylphosphatidylethanolamine (L1).

All FSL constructs disperse in biocompatible media and spontaneously and stably incorporate into cell membranes. Cells modified with KODE™ constructs are known as kodecytes<sup>2</sup> and usually maintain their normal vitality and functionality.

Acquired-B antigen expression is usually caused by a bacterial infection that causes *in vivo* deacetylation of blood group A antigen. This may result in non-blood group B reactivity with some anti- B reagents<sup>1</sup>. FSL-AcqB(tri) has been specifically designed to create cells (kodecytes) expressing blood group Acquired-B antigens but can also be used to modify other hydrophobic surfaces including fixed cells and solid phase surfaces. This product can be used to attach reproducible and controlled levels of blood group acquired-B antigens to group O erythrocytes<sup>3</sup>. Acquired-B kodecytes should react with most anti-B and anti-A,B blood grouping reagents that also show reactivity against acquired-B antigen<sup>3</sup>.

### Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices

MSDS sheets and other technical information is available at [kodebiotech.com/sales/order\\_home.php](http://kodebiotech.com/sales/order_home.php)

### End User License

This product is subject to the terms of an End User License – a copy of this license is available at [kodebiotech.com/sales/order\\_home.php](http://kodebiotech.com/sales/order_home.php)

### Preparation Instructions

The product should be reconstituted at a concentration of 5 mg/ml in saline or PBS. Buffered solutions are preferred for long-term storage. Product should not be reconstituted in water unless for immediate use as product is unstable when stored in water. The 5 mg/ml Stock Solution can be frozen for later usage. Thawed product should be briefly sonicated before use.

Stock Solutions can be diluted in buffers containing protein. Stock solutions should not be diluted in buffers containing lipids (e.g. serum) or other hydrophobic products as the FSL will associate with this material and insertion into cells will be reduced.

### Storage/Stability

Store unopened product at below minus 10 °C  
Store 5 mg/ml Stock Solution at below minus 10 °C and avoid repeated freezing and thawing.

Solutions in PBS, pH 7, can be stored at 2-8 °C for up to 2 weeks.

### Product Profile

Cell labeling – Add 1 volume of FSL-AcqB(tri) diluted in PBS to 1 volume of cells. A 5 mg/ml FSL-AcqB(tri) solution will give reactivity expected of acquired-B red cells<sup>3</sup>. Incubate for 2 hours at a temperature of 37 °C to allow molecules to spontaneously insert into cell membranes. Wash. Store kodecytes in serum free media.

Rate of FSL insertion is primarily determined by FSL concentration, time and temperature.

FSL constructs will remain in active cell membranes for up to 12 hours and indefinitely in inactive membranes (such as red cells) in serum-free media.

### References

1. *Vox Sang* 1975; 28:398
2. *Current Opinions in Haematology* 2009; 16(6):467-472
3. *Transfusion* 2007; 47: 876-882

FSL-ACB(GALN(Ac-)a3[Fa2]GALb)-SA1-L1 catalogue 149554-1-R&D is sold  
for Research and Development purposes only  
and is subject to the following End-User License

**KODE™ Construct End User License (Non-Commercial Research Purposes)**

KODE™ Constructs are supplied by KODE Biotech Materials Limited under license from KODE Biotech Limited. As the entity, which has purchased a KODE™ Construct, you have the non-transferable right to use the purchased KODE™ Construct for research conducted by you, for your own internal purposes, in accordance with the provisions of this document.

You may not use the purchased KODE™ Construct, or any composition comprising the purchased KODE™ Construct (including modified cells or "kodecytes"), for any commercial purpose.

'Commercial purposes' mean any activity for which you obtain a financial or in-kind benefit from another entity, including manufacture of products for sale or other disposition, and the conduct of research or other services for or on behalf of a third party or where a third party has any option or right of refusal over research outcomes.

Transfer to a third party is permitted where the third party is a genuine scientific collaborator and has agreed in writing to be bound by the provisions of this document prior to the transfer. You are responsible for ensuring that your personnel and scientific collaborators comply with the restrictions provided in this document.

Your purchase of the KODE™ Construct does not give you any license of, or interest in, any intellectual property rights of KODE Biotech Limited other than as may be necessary for your internal research as permitted by this document. The KODE™ Construct is supplied "as is" and neither KODE Biotech Limited nor the supplier gives any warranty that the purchased KODE™ Construct is fit for any particular purpose or that it has any particular qualities or characteristics.